Maes Edmond F, Diop Ousmane M, Jorba Jaume, Chavan Smita, Tangermann Rudolph H, Wassilak Steven G F
MMWR Morb Mortal Wkly Rep. 2017 Apr 7;66(13):359-365. doi: 10.15585/mmwr.mm6613a3.
Global measures to eradicate polio began in 1988; as of 2014, four of six World Health Organization (WHO) regions have been certified polio-free. Within the two endemic regions (African and Eastern Mediterranean), Nigeria, Afghanistan, and Pakistan have never interrupted transmission of wild poliovirus (WPV) (1). The primary means of detecting poliovirus transmission is surveillance for acute flaccid paralysis (AFP) among children aged <15 years, combined with collection and testing of stool specimens from persons with AFP for detection of WPV and vaccine-derived polioviruses (VDPVs) (viruses that differ genetically from vaccine viruses and can emerge in areas with low vaccination coverage and cause paralysis) in WHO-accredited laboratories within the Global Polio Laboratory Network (2,3). AFP surveillance is supplemented by environmental surveillance for polioviruses in sewage from selected locations (4). Genomic sequencing of the VP1-coding region of isolated polioviruses enables mapping transmission by time and place, assessment of potential gaps in surveillance, and identification of the emergence of VDPVs. This report presents poliovirus surveillance data from 2015 and 2016, with particular focus on 20 countries in the African Region and six in the Eastern Mediterranean Region that reported WPV or circulating VDPVs (cVDPVs) during 2011-2016, as well as the three countries most affected by the 2014-2015 Ebola virus disease (Ebola) outbreak (Guinea, Liberia, and Sierra Leone). During 2016, 12 (60%) of the 20 African Region countries and all six of the Eastern Mediterranean Region countries met both surveillance quality indicators (nonpolio AFP rates of ≥2 per 100,000 persons aged <15 years per year and ≥80% of AFP cases with adequate stool specimens [stool adequacy]) at the national level; however, provincial-level variation was seen. To complete and certify polio eradication, surveillance gaps must be identified and surveillance activities, including supervision, monitoring, and specimen collection and handling, further strengthened.
全球根除脊髓灰质炎行动始于1988年;截至2014年,世界卫生组织(WHO)六个区域中的四个已被认证为无脊髓灰质炎区域。在两个脊髓灰质炎流行区域(非洲区域和东地中海区域),尼日利亚、阿富汗和巴基斯坦从未中断野生脊髓灰质炎病毒(WPV)的传播(1)。检测脊髓灰质炎病毒传播的主要手段是对15岁以下儿童的急性弛缓性麻痹(AFP)进行监测,并从AFP患者中采集粪便标本并进行检测,以在全球脊髓灰质炎实验室网络内的WHO认可实验室中检测WPV和疫苗衍生脊髓灰质炎病毒(VDPV)(在基因上与疫苗病毒不同且可在疫苗接种覆盖率低的地区出现并导致麻痹的病毒)(2,3)。AFP监测通过对选定地点污水中的脊髓灰质炎病毒进行环境监测得到补充(4)。对分离出的脊髓灰质炎病毒的VP1编码区进行基因组测序能够按时间和地点绘制传播图谱,评估监测中的潜在差距,并识别VDPV的出现。本报告展示了2015年和2016年的脊髓灰质炎病毒监测数据,特别关注在2011 - 2016年期间报告了WPV或循环VDPV(cVDPV)的非洲区域20个国家和东地中海区域6个国家,以及受2014 - 2015年埃博拉病毒病(埃博拉)疫情影响最严重的三个国家(几内亚、利比里亚和塞拉利昂)。2016年,非洲区域20个国家中的12个(60%)以及东地中海区域所有6个国家在国家层面均达到了两项监测质量指标(每年每10万15岁以下人群中非脊髓灰质炎AFP发病率≥2例以及≥80%的AFP病例有足够的粪便标本[粪便充足率]);然而,省级层面存在差异。为完成并认证根除脊髓灰质炎,必须识别监测差距,并进一步加强包括监督、监测以及标本采集和处理在内的监测活动。